デュピクセントの薬剤に関する洞察と市場予測：2032年

デュピルマブはヒト型モノクローナルIgG4抗体で、IL-4とIL-13の受容体複合体に共通するIL-4Rαサブユニットに特異的に結合することにより、IL-4とIL-13のシグナル伝達を阻害します。i型受容体を介したIL-4シグナル伝達と、II型受容体を介したIL-4およびIL-13シグナル伝達を阻害します。デュピクセントの臨床試験のデータから、IL-4とIL-13がアトピー性皮膚炎、喘息、鼻ポリポーシスを伴う慢性鼻副鼻腔炎（CRSwNP）、EoEで主要な役割を果たす2型炎症の主要な 促進要因であることが示されています。デュピルマブでIL-4Rαを阻害すると、炎症性サイトカイン、ケモカイン、一酸化窒素、IgEの放出を含むIL-4およびIL-13サイトカイン誘発炎症反応が抑制されます。デュピルマブは、リジェネロン社独自のVelocImmune技術を用いて開発されました。VelocImmuneは完全ヒト型モノクローナル抗体を製造する独自の技術です。

同社によると、デュピクセントは12歳以上のEoE患者において臨床的に意味のある良好な第III相試験結果を示した最初で唯一の生物学的製剤です。同社はまた、活動性EoEの小児患者を対象とした第III相試験（EoE KIDS）でもデュピルマブを評価しています。さらに、FDAはBTD、ODD、PRを承認しています。

今後数年間で、好酸球性食道炎（EoE）の市場シナリオは、世界中の広範な調査と医療支出の増加により変化するとみられます。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、デュピクセントの優位性に影響を与える可能性のある機会を模索しています。EoEに対する他の新興製品がデュピクセントに厳しい市場競争を挑むことが予想され、近い将来に後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるデュピクセント市場について調査し、好酸球性食道炎（EoE）治療薬であるデュピクセント市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 好酸球性食道炎（EoE）に対するデュピクセントの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 デュピクセント市場評価

• EoEに対するデュピクセントの市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるEoEに対するデュピクセントの市場規模
• 国国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: DUPIXENT, Clinical Trial Description, 2023
• Table 2: DUPIXENT, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: DUPIXENT Market Size in the 7MM, in USD million (2019-2032)
• Table 6: DUPIXENT Market Size in the US, in USD million (2019-2032)
• Table 7: DUPIXENT Market Size in Germany, in USD million (2019-2032)
• Table 8: DUPIXENT Market Size in France, in USD million (2019-2032)
• Table 9: DUPIXENT Market Size in Italy, in USD million (2019-2032)
• Table 10: DUPIXENT Market Size in Spain, in USD million (2019-2032)
• Table 11: DUPIXENT Market Size in the UK, in USD million (2019-2032)
• Table 12: DUPIXENT Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: DUPIXENT Market Size in the 7MM, USD million (2019-2032)
• Figure 2: DUPIXENT Market Size in the United States, USD million (2019-2032)
• Figure 3: DUPIXENT Market Size in Germany, USD million (2019-2032)
• Figure 4: DUPIXENT Market Size in France, USD million (2019-2032)
• Figure 5: DUPIXENT Market Size in Italy, USD million (2019-2032)
• Figure 6: DUPIXENT Market Size in Spain, USD million (2019-2032)
• Figure 7: DUPIXENT Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: DUPIXENT Market Size in Japan, USD million (2019-2032)

“"DUPIXENT Drug Insight and Market Forecast - 2032" report provides comprehensive insights about DUPIXENT for Eosinophilic esophagitis (EoE) in the seven major markets. A detailed picture of the DUPIXENT for EoE in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the DUPIXENT for EoE. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DUPIXENT market forecast analysis for EoE in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in EoE.

Drug Summary:

Dupilumab is a human monoclonal IgG4 antibody that inhibits IL-4 and IL-13 signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes. It inhibits IL-4 signaling via the type I receptor and IL-4 and IL-13 signaling through the type II receptor. Data from DUPIXENT clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and EoE. Blocking IL-4Rα with dupilumab inhibits IL-4 and IL-13 cytokine-induced inflammatory responses, including the release of pro-inflammatory cytokines, chemokines, nitric oxide, and IgE. Dupilumab was invented using Regeneron's proprietary VelocImmune technology. VelocImmune is a unique technology for producing fully human monoclonal antibodies.

According to the company, DUPIXENT is the first and only biologic to show positive and clinically-meaningful Phase III results in patients 12 years and older with EoE. The company is also evaluating dupilumab in Phase III (EoE KIDS) study in pediatric patients with active EoE. Additionally, FDA has granted BTD, ODD, and PR.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the DUPIXENT description, mechanism of action, dosage and administration, research and development activities in eosinophilic esophagitis (EoE).
• Elaborated details on DUPIXENT regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DUPIXENT research and development activities in EoE across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around DUPIXENT.
• The report contains forecasted sales of DUPIXENT for EoE till 2032.
• Comprehensive coverage of the late-stage emerging therapies for EoE.
• The report also features the SWOT analysis with analyst views for DUPIXENT in EoE.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DUPIXENT Analytical Perspective by DelveInsight

In-depth DUPIXENT Market Assessment

This report provides a detailed market assessment of DUPIXENT for eosinophilic esophagitis (EoE) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

DUPIXENT Clinical Assessment

The report provides the clinical trials information of DUPIXENT for EoE covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for eosinophilic esophagitis (EoE) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DUPIXENT dominance.
• Other emerging products for EoE are expected to give tough market competition to DUPIXENT and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DUPIXENT in EoE.
• Our in-depth analysis of the forecasted sales data of DUPIXENT from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DUPIXENT in EoE.

Key Questions:

• What is the product type, route of administration and mechanism of action of DUPIXENT?
• What is the clinical trial status of the study related to DUPIXENT in eosinophilic esophagitis (EoE) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DUPIXENT development?
• What are the key designations that have been granted to DUPIXENT for EoE?
• What is the forecasted market scenario of DUPIXENT for EoE?
• What are the forecasted sales of DUPIXENT in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to DUPIXENT for EoE?
• Which are the late-stage emerging therapies under development for the treatment of EoE?

Table of Contents

1. Report Introduction

2. DUPIXENT Overview in EoE

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. DUPIXENT Market Assessment

• 5.1. Market Outlook of DUPIXENT in EoE
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of DUPIXENT in the 7MM for EoE
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of DUPIXENT in the United States for EoE
  • 5.3.2. Market Size of DUPIXENT in Germany for EoE
  • 5.3.3. Market Size of DUPIXENT in France for EoE
  • 5.3.4. Market Size of DUPIXENT in Italy for EoE
  • 5.3.5. Market Size of DUPIXENT in Spain for EoE
  • 5.3.6. Market Size of DUPIXENT in the United Kingdom for EoE
  • 5.3.7. Market Size of DUPIXENT in Japan for EoE

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options